Cardiovascular

Cardiovascular

The world looks to the DCRI as the definitive leader in cardiovascular clinical research, implementation science, and education. We look to our practicing faculty, cutting-edge analytics, and operational expertise to address a spectrum of challenges through clinical research focused on improving care and outcomes for patients with cardiovascular disease.

The Next CV Advancement Begins Here

The Cardiovascular Clinical Trials group advances and streamlines the process through innovative study design, fit-for-purpose approaches, thoughtful analytics, and a commitment to rapid knowledge dissemination. This is essential to translate novel therapeutic concepts into effective and efficient clinical trials across the spectrum of cardiovascular illnesses.

CV Outcomes Research

The demand to clearly and quickly demonstrate outcomes of new therapies for cardiovascular patients is greater now than ever before. And the DCRI is the national leader in helping sponsors do that—collecting and analyzing economic and quality-of-life data for the purpose of overcoming barriers to reimbursement.

DCRI’s Health Services Research Outcomes group maintains the world’s oldest and largest ongoing database for cardiovascular disease and is conducting groundbreaking pragmatic clinical trials for patients with heart disease.

With 21 full-time faculty and 100 full-time statisticians, project managers, and research and operational team members, the DCRI Outcomes Research team evaluates outcomes and costs in phase II through IV clinical trials and observational research studies.

Testing for Cardiovascular Devices

The DCRI has a team of experts specifically dedicated to providing critical guidance and support for the unique challenges faced by devices trials, such as evolving regulatory requirements and the need for rapid recruitment of eligible patients.

Highlights

Encouraging Cardiologists to Work With Other Providers

COORDINATE-Diabetes, an implementation study led by the DCRI, focuses on helping cardiology clinics to coordinate with endocrinologists and primary care providers when caring for patients with cardiovascular disease and Type 2 diabetes.

Examining How Treatments Are Used in Real-World Practice

The DCRI is working with Amgen to enroll 8,500 patients in a large registry that will enable researchers to examine how PCSK9 inhibitors and other treatments for lipid management are used in real-world practice.

When Does Aspirin Stop Providing Benefit?

A secondary analysis of AUGUSTUS found that 30 days of aspirin therapy may provide benefit without introducing risk for patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention.

Advancing the Field of Racial Health Disparities in Cardiovascular Research

Kevin Thomas, MD, discusses the ways in which his group attempts to move past describing racial disparities in treatment and outcomes and toward identifying causes of the disparities and interventions that would help bridge the gap, particularly as it pertains to cardiovascular care.

Cardiovascular Leadership at the DCRI

G. Michael Felker, MD, Director

G. Michael Felker, MD, MHS, is Professor of Medicine with tenure in the Division of Cardiology at Duke University Medical Center and the head of Cardiovascular Research at the DCRI. He served as Chief of the Heart Failure Section at Duke University School of Medicine from 2013 to 2020. Felker completed his medical training at Duke University School of Medicine, his internal medicine training at Johns Hopkins Hospital where he was chief resident, and his cardiology training at Duke. Felker’s research focus is on clinical trials in acute and chronic heart failure and the use of biomarkers as diagnostics, prognostic, and therapeutic tools in heart failure.

Felker has published more than 320 peer reviewed articles and book chapters in the field of heart failure. He has served on the executive and steering committees for multiple national and international clinical trials in heart failure. He directs the Advanced Heart Failure Transplant Cardiology Fellowship Training Program at Duke University School of Medicine. Felker is an editorial board member or peer reviewer for multiple high-impact medical journals, including the New England Journal of Medicine, JAMA, Lancet, Circulation, and JACC. He is the Associate Editor of JACC: Heart Failure and co-editor of Heart Failure: A Companion to Braunwald’s Heart Disease, the leading heart failure textbook. He is a member of the Heart Failure Society of America Board of Directors.

WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.